Physician profile
Arnold Deleon
NPI 1104001148
$14,448.76
in general payments reported to CMS, 2019-2025
46 companies · $1,774 in 2025
The $1,774 reported for 2025 was more than what 80% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $1,448 · 2021: $2,825 · 2022: $2,958 · 2023: $2,058 · 2024: $1,711 · 2025: $1,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,042 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,042.38 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,857.01 | 2019-2025 | Proclaim, Eterna, Ionicrf |
| Boston Scientific Corporation | $941.38 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Nevro Corp. | $826.77 | 2019-2023 | Senza |
| Si-Bone, INC. | $509.67 | 2019-2025 | |
| Zavation Medical Products, LLC | $500.00 | 2023 | |
| Medtronic, INC. | $356.44 | 2021-2025 | Catalyft Pl Expandable Interbody System, Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $331.10 | 2019-2025 | Belbuca, Xtampza |
| Nalu Medical, INC. | $324.58 | 2024-2025 | Nalu Neurostimulation System |
| Genesys Orthopedics Systems, L.L.C. | $322.25 | 2022 | |
| Curonix LLC | $259.20 | 2022-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medtronic USA, INC. | $257.61 | 2019-2020 | |
| Globus Medical, INC. | $256.14 | 2025 | Vyrsa V1, Senza |
| Scilex Pharmaceuticals INC. | $218.94 | 2019-2023 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.56 | 2020-2025 | Relistor |
| Abbvie INC. | $157.87 | 2021-2024 | Qulipta, Botox |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.